Guobang Pharma Ltd. (SHA:605507)
China · Delayed Price · Currency is CNY 23.86
-0.11 (-0.46%)
Apr 28, 2026, 3:00 PM CST
Guobang Pharma Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 766.47 | 820.82 | 781.6 | 612.46 | 920.9 | 706.03 |
Depreciation & Amortization | 476.96 | 476.96 | 433.38 | 321.14 | 260.29 | 201.12 |
Other Amortization | 1.13 | 1.13 | 0.57 | 1.24 | 1.5 | 1.18 |
Loss (Gain) From Sale of Assets | -24.81 | -24.81 | 9.11 | - | 0.05 | -0.3 |
Asset Writedown & Restructuring Costs | 7.67 | 7.67 | 6.54 | 5.08 | 15.84 | 61.14 |
Loss (Gain) From Sale of Investments | -29.58 | -29.58 | -27.64 | -23.56 | -24.09 | -10.53 |
Provision & Write-off of Bad Debts | 5.65 | 5.65 | 12.07 | -7.17 | 11.72 | 0.92 |
Other Operating Activities | 646.42 | 47.22 | 25.48 | 43.28 | 9.44 | 33.35 |
Change in Accounts Receivable | 258.28 | 258.28 | -634.31 | -929.35 | -255.53 | -841.81 |
Change in Inventory | -439.76 | -439.76 | -20.68 | 9.2 | -127.53 | -371.61 |
Change in Accounts Payable | -562.84 | -562.84 | 120.73 | 488.71 | 179.69 | 48.23 |
Change in Other Net Operating Assets | 6.35 | 6.35 | 4.87 | -2.47 | 4.56 | 1.62 |
Operating Cash Flow | 1,104 | 559.28 | 706.41 | 516.76 | 1,017 | -176.18 |
Operating Cash Flow Growth | 154.49% | -20.83% | 36.70% | -49.19% | - | - |
Capital Expenditures | -328.11 | -277.71 | -419.12 | -748.44 | -803.12 | -448.04 |
Sale of Property, Plant & Equipment | 24.1 | 24.1 | 17.96 | 24.9 | 17.81 | 4.34 |
Investment in Securities | -480.73 | -597.85 | -112.68 | 362.07 | 373.54 | -1,252 |
Other Investing Activities | 1.99 | - | - | - | 0 | 5.65 |
Investing Cash Flow | -782.74 | -851.46 | -513.85 | -361.47 | -411.76 | -1,690 |
Short-Term Debt Issued | - | - | - | 1 | 1 | - |
Long-Term Debt Issued | - | 1,032 | 593.21 | 964 | 778.11 | 364.43 |
Total Debt Issued | 796.76 | 1,032 | 593.21 | 965 | 779.11 | 364.43 |
Short-Term Debt Repaid | - | - | - | -1 | -1 | - |
Long-Term Debt Repaid | - | -813.79 | -782.29 | -656.5 | -283 | -1,115 |
Total Debt Repaid | -804.6 | -813.79 | -782.29 | -657.5 | -284 | -1,115 |
Net Debt Issued (Repaid) | -7.84 | 218.24 | -189.08 | 307.5 | 495.11 | -750.3 |
Issuance of Common Stock | 184.58 | 184.58 | 97.11 | - | - | 2,677 |
Repurchase of Common Stock | -166.14 | -166.14 | -101.01 | - | - | - |
Common Dividends Paid | -361 | -359.63 | -194.1 | -361.64 | -128.21 | -333.74 |
Other Financing Activities | 7.04 | - | 0.58 | 8.2 | 0.05 | -22.18 |
Financing Cash Flow | -343.36 | -122.95 | -386.49 | -45.94 | 366.95 | 1,571 |
Foreign Exchange Rate Adjustments | -14.21 | -1.36 | 27.08 | 10.71 | 35.27 | -9.93 |
Net Cash Flow | -36.18 | -416.49 | -166.85 | 120.07 | 1,007 | -305.43 |
Free Cash Flow | 776.02 | 281.57 | 287.29 | -231.68 | 213.92 | -624.23 |
Free Cash Flow Growth | 671.63% | -1.99% | - | - | - | - |
Free Cash Flow Margin | 12.74% | 4.68% | 4.88% | -4.33% | 3.74% | -13.86% |
Free Cash Flow Per Share | 1.41 | 0.51 | 0.52 | -0.42 | 0.38 | -1.22 |
Cash Income Tax Paid | 57.42 | 61.76 | 48.15 | -100.85 | 31.61 | 36.92 |
Levered Free Cash Flow | 737.83 | 171.74 | 48.34 | 134.75 | 340.79 | -852.93 |
Unlevered Free Cash Flow | 752.77 | 186.69 | 65.39 | 148.86 | 351.13 | -834.98 |
Change in Working Capital | -745.78 | -745.78 | -534.69 | -435.71 | -178.6 | -1,169 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.